MyoKardia Inc fka MYOK

[Whalatane]

Bernstein
Altho small numbers in trial results were statistically significant ...primary end pt ..p=0.002
Clinically and statistically significant improvements were also observed in peak VO2 ...p =0.004

So very low possibility that these benefits were simply by chance .

Sanofi is a partner and they would have certainly done their DD before investing . They certainly now have a lot of cash ...the capital raise went out at a premium !
They will almost certainly apply for fast track and possibly break thru staus which will enable rolling submissions of data and cut probably 18 mths off development time to FDA approval.

The form 4's you referenced were pre planned sales .

Kiwi